Amgen prevails against Sanofi and Regeneron
26-02-2019
Sanofi and Regeneron secure stay of Praluent injunction
10-02-2017
nitpicker / Shutterstock.com
French drugmaker Sanofi and US biotechnology company Regeneron have secured a victory at the European Patent Office, which has sided in their favour by ruling that a patent belonging to rival Amgen is invalid.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Sanofi, Regeneron, Amgen, patent, enablement, Repatha, Praluent, big pharma, biotechnology
